R-N-Propylnorapomorphine

R-N-Propylnorapomorphine

SCHEMBL7997518

CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 6/20 1.00
▸ DRD3 P35462 5/20 1.00
▸ TH P07101 4/20 1.00
▸ MAPT P10636 4/20 1.00
▸ MAPK1 P28482 4/20 1.00
▸ DRD1 P21728 4/20 1.00
▸ KDM4E B2RXH2 3/20 1.00
▸ LMNA P02545 3/20 1.00
▸ HPGD P15428 3/20 1.00
▸ PMP22 Q01453 3/20 1.00
▸ KMT2A Q03164 3/20 1.00
▸ GMNN O75496 2/20 1.00
▸ GFER P55789 2/20 1.00
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ TDP1 Q9NUW8 2/20 1.00
▸ RGS12 O14924 2/20 1.00
▸ TP53 P04637 2/20 1.00
▸ CYP1A2 P05177 2/20 1.00
▸ CYP2D6 P10635 2/20 1.00
▸ THPO P40225 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
R-N-Propylnorapomorphine SCHEMBL13487203 1.00 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
R-N-Propylnorapomorphine SCHEMBL29447877 1.00 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
R-N-Propylnorapomorphine SCHEMBL249729 1.00 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
R-N-Propylnorapomorphine SCHEMBL13398114 1.00 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
SCHEMBL14161595 0.91 MAPT (0.83) DRD2DRD3THMAPTMAPK1
SCHEMBL1203698 0.90 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
SCHEMBL10754712 0.90 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
SCHEMBL1203699 0.90 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
SCHEMBL19815875 0.89 DRD2 (1.00) DRD2DRD3THMAPTMAPK1
Hydrochloric Acid SCHEMBL10752801 0.88 DRD2 (0.98) DRD2DRD3THMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166531-A1 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF THE MCLEAN HOSPITAL CORPORATION 2017-06-15 — — US disclosed
US-20170166531-A1 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF THE MCLEAN HOSPITAL CORPORATION 2017-06-15 — — US disclosed
US-9517279-B2 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof THE MCLEAN HOSPITAL CORPORATION (US) 2016-12-13 — — US disclosed
US-9517279-B2 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof THE MCLEAN HOSPITAL CORPORATION (US) 2016-12-13 — — US disclosed
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2014-09-18 — — US disclosed
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2014-09-18 — — US disclosed
US-20130209362-A1 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF THE MCLEAN HOSPITAL CORPORATION (US) 2013-08-15 — — US disclosed
US-20130209362-A1 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF THE MCLEAN HOSPITAL CORPORATION (US) 2013-08-15 — — US disclosed
WO-2013074059-A2 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2013-05-23 — — WO disclosed
US-8431591-B2 R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof THE MCLEAN HOSPITAL CORPORATION (US) 2013-04-30 — — US disclosed
WO-2011130530-A1 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF THE MCLEAN HOSPITAL CORPORATION (US) 2011-10-20 — — WO disclosed
US-20110218158-A1 DNA CYTOSINE DEAMINASE INHIBITORS REGENTS OF THE UNIVERSITY OF MINNESOTA 2011-09-08 — — US disclosed
US-20110218158-A1 DNA CYTOSINE DEAMINASE INHIBITORS REGENTS OF THE UNIVERSITY OF MINNESOTA 2011-09-08 — — US disclosed
US-20110190307-A1 Assay UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2011-08-04 — — US disclosed
US-20110190307-A1 Assay UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2011-08-04 — — US disclosed
US-20110034446-A1 R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF THE MCLEAN HOSPITAL CORPORATION (US) 2011-02-10 — — US disclosed
WO-2010033986-A2 DNA CYTOSINE DEAMINASE INHIBITORS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2010-03-25 — — WO disclosed
WO-2009156728-A1 ASSAY UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218158-A1 DNA CYTOSINE DEAMINASE INHIBITORS DCTD, APOBEC3A, UNG DRD2 2058/4885DRD3 1665/4885TH 2059/4885
US-20130209362-A1 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF HTR5A, HTR2C, HTR3A DRD2 11/4885DRD3 32/4885TH 278/4885
US-20110190307-A1 Assay SMN1; SMN2, CHAT, CLN6 DRD2 1785/4885DRD3 1687/4885TH 2249/4885
US-20110034446-A1 R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF SNCA, HTR3A, PARK7 DRD2 18/4885DRD3 35/4885TH 119/4885
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION CDA, DCTD, ADA DRD2 2443/4885DRD3 3073/4885TH 2499/4885
US-20170166531-A1 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF HTR5A, HTR2C, HTR3A DRD2 11/4885DRD3 32/4885TH 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback